spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Amphotericin B 

 HSMN NewsFeed - 11 Feb 2019
FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Jan 2016
iCo Strategic Reorganization
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Sep 2015
Matinas BioPharma Appoints Cochleate Technology Pioneer Raphael J. Mannino, Ph.D., as Senior Vice President and Chief Technology Officer
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 4 Feb 2015
Third Rock Ventures Launches REVOLUTION Medicines with $45 Million Series A to Redesign Evolution’s Products to Treat Serious Diseases
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 31 Jan 2014
Mylan Named as Gilead's Exclusive Branded Medicines Business Partner for India
Biopharmaceuticals Distribution
 HSMN NewsFeed - 25 Oct 2010
Kadmon Pharmaceuticals Acquires Three Rivers Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 24 Mar 2009
FDA Approves New Indication for Wyeth's TYGACIL (tigecycline) for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 May 2008
Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Mar 2008
Accentia Biopharmaceuticals Announces Results on Primary Endpoint in Clinical Study of SinuNase Lavage
Biopharmaceuticals
 HSMN NewsFeed - 24 Oct 2007
FDA Accepts Wyeth's Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
Biopharmaceuticals
 HSMN NewsFeed - 8 Oct 2007
Accentia Biopharmaceuticals Announces Completion of Enrollment in Fast-Tracked Pivotal Phase 3 Clinical Trial of SinuNase for Chronic Sinusitis
Biopharmaceuticals
 HSMN NewsFeed - 18 Sep 2007
New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
Biopharmaceuticals
 HSMN NewsFeed - 17 Sep 2007
Study Presented on Use of CANCIDAS(R) (caspofungin acetate) as Empirical Therapy of Suspected Invasive Fungal Infections in Pediatric Patients with Persistent Fever and Neutropenia
Biopharmaceuticals
 HSMN NewsFeed - 15 Aug 2007
Accentia Biopharmaceuticals Updates Interim Analysis of Blinded Clinical Results in the Fast-Tracked Pivotal Phase 3 Trial of SinuNase for the Treatment of Refractory Chronic Sinusitis
Biopharmaceuticals
 HSMN NewsFeed - 14 Aug 2007
BDSI Names David Blum, M.D. Vice President of Medical Affairs and Clinical Research
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Jun 2007
Phase 2 Clinical Results of Ganite(R) Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 May 2007
Accentia Biopharmaceuticals Makes Milestone Payment Based on Fast Tracked Pivotal Phase 3 Study with SinuNase for the Treatment of Chronic Sinusitis
Biopharmaceuticals
 HSMN NewsFeed - 10 Apr 2007
BioDelivery Sciences Names Al Medwar as Vice President of Marketing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Feb 2007
BDSI Announces FDA Acceptance of Bioral(R) Amphotericin IND
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 21 Dec 2006
Accentia Biopharmaceuticals in Discussions with Pharmaceutical Companies on SinuNase Partnership
Biopharmaceuticals
 HSMN NewsFeed - 6 Nov 2006
Accentia Biopharmaceuticals Commences Fast-Tracked Phase 3 Clinical Trial of SinuNase for the Treatment of Chronic Sinusitis
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Sep 2006
European Commission Grants Orphan Medicinal Product Designation to Nektar's Amphotericin B Inhalation Powder (ABIP) for the Prevention of Pulmonary Fungal Infections in Patients Deemed At Risk
Biopharmaceuticals Drug Delivery Regulatory
 HSMN NewsFeed - 22 May 2006
FDA Grants Fast Track Designation to Nektar's Amphotericin B Inhalation Powder (ABIP) for Prevention of Pulmonary Fungal Infections in At-Risk Patients
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 36

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 36 additional stories matching:
Amphotericin B
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.